EDELMAN JOSEPH (CIK 1164426) reported 26 SEC Form 4 insider transactions across 9 companies over the past 18 months (most recent 2026-08-27). Recent activity: Buy IMTX (863,060 shares), Buy FRNM (5.5M shares), Buy KARD (20,706 shares), Buy MGTX (555,555 shares), Sell MGTX (2.3M shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | Immatics N.V. (IMTX) | Director | Buy | 863,060 | $7.5M |
| 2026-07-22 | Freenome, Inc. (FRNM) | 10% Owner | Buy | 5.5M | $55.0M |
| 2026-07-13 | Kardigan, Inc. (KARD) | Director | Buy | 20,706 | $0 |
| 2026-04-23 | MeiraGTx Holdings plc (MGTX) | Director | Buy | 555,555 | $5.0M |
| 2026-01-02 | MeiraGTx Holdings plc (MGTX) | Director | Sell | 2.3M | $18.2M |
| 2025-12-23 | Athira Pharma, Inc. (ATHA) | Director | Buy | 989,270 | $6.3M |
| 2025-12-23 | Athira Pharma, Inc. (ATHA) | Director | Buy | 329,756 | $2.1M |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 3,213 | $12,531 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 537 | $2,314 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 7,862 | $31,920 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 883 | $3,585 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 28,597 | $111,528 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 4,783 | $20,615 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 28,902 | $149,712 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 3,247 | $16,819 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 17,746 | $84,294 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 1,993 | $9,467 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 16,633 | $75,514 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | 10% Owner | Sell | 1,869 | $8,485 |
| 2025-08-05 | Orchestra BioMed Holdings, Inc. (OBIO) | 10% Owner | Buy | 700,000 | $1.9M |
| 2025-05-01 | Acrivon Therapeutics, Inc. (ACRV) | 10% Owner | Sell | 437,881 | $617,412 |
| 2025-05-01 | Acrivon Therapeutics, Inc. (ACRV) | 10% Owner | Sell | 298,886 | $400,507 |
| 2025-04-29 | Acrivon Therapeutics, Inc. (ACRV) | 10% Owner | Sell | 250,000 | $352,500 |
| 2025-04-29 | Acrivon Therapeutics, Inc. (ACRV) | 10% Owner | Sell | 1.1M | $2.1M |
| 2025-04-29 | Acrivon Therapeutics, Inc. (ACRV) | 10% Owner | Sell | 215,283 | $335,841 |
来源：SEC Form 4 申报文件 · 截至 2026-08-27